The Icahn School of Medicine at Mount Sinai in New York recently discovered that dupilumab, a drug used to treat allergies, can enhance the immunity of lung cancer patients and help control the disease.Results December 6publishIn the journal Nature.
In a small clinical trial, the team combined treatment with dupilumab (an antibody drug commonly used to treat allergies and asthma) on lung cancer patients who could not be controlled by immune checkpoint inhibitor drugs. As a result, the patient’s immune system was strengthened, and one of the six patients had almost no tumors. Completely disappear.
Advertisement (Please continue reading this article)
Although immune checkpoint inhibition has revolutionized cancer treatment in recent years, it is only effective for about one-third of patients, and the effects are often not long-lasting. To overcome shortcomings, scientists at the Icahn School of Medicine at Mount Sinai used advanced “single-cell nucleic acid sequencing technology” combined with artificial intelligence to analyze patient tumor samples to first identify factors that may hinder immune checkpoint inhibition therapy.
The team noticed that the characteristics of lung cancer tumor immune cells have many similarities with immune cells from allergic diseases such as eczema and asthma, leading them to think about whether allergic disease drugs can be used to help treat cancer. Experiments have shown that dupilumab can enhance the immunity of lung cancer patients and make immune checkpoint inhibition therapy effective. After one patient received three doses of anti-allergy drugs, his cancer almost disappeared and he is still under stable control today, more than 17 months later.
The researchers were encouraged by the preliminary results, but stressed that larger clinical trials are needed to prove the efficacy of dupilumab. The team is now expanding its clinical scope to combine dupilumab with multiple immune checkpoint inhibitor drugs, looking for tests that can predict which patients will benefit from dupilumab treatment.
Advertisement (Please continue reading this article)
(Source of first picture:DUPIXENT）
2023-12-15 15:11:27
#scientists #discovered #antiallergy #drug #ingredients #immune #checkpoint #suppression #therapy #save #patients #Science #Technology #News #LINE #TODAY
